Cargando…

Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation

Lysophosphatidic acid (LPA), which is proposed to play an important role in normal physiological situations such as wound healing, vascular tone, vascular integrity and reproduction, may be involved in the etiology of some diseases such as atherosclerosis, cancer, obesity or myocardial infarction. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhen-Guang, Yu, Zhan-Cai, Yu, Yong-Peng, Ju, Wei-Ping, Wang, Dao-Zhen, Zhan, Xia, Wu, Xi-Juan, Zhou, Li
Formato: Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996775/
https://www.ncbi.nlm.nih.gov/pubmed/21152315
http://dx.doi.org/10.3390/ijms11103988
_version_ 1782193222982828032
author Li, Zhen-Guang
Yu, Zhan-Cai
Yu, Yong-Peng
Ju, Wei-Ping
Wang, Dao-Zhen
Zhan, Xia
Wu, Xi-Juan
Zhou, Li
author_facet Li, Zhen-Guang
Yu, Zhan-Cai
Yu, Yong-Peng
Ju, Wei-Ping
Wang, Dao-Zhen
Zhan, Xia
Wu, Xi-Juan
Zhou, Li
author_sort Li, Zhen-Guang
collection PubMed
description Lysophosphatidic acid (LPA), which is proposed to play an important role in normal physiological situations such as wound healing, vascular tone, vascular integrity and reproduction, may be involved in the etiology of some diseases such as atherosclerosis, cancer, obesity or myocardial infarction. Abnormal findings, including silent brain infarction (SBI), are frequently observed by magnetic resonance imaging (MRI) in patients with nonvalvular atrial fibrillation (NVAF). However, whether there is a relationship between LPA level and the prevalence of SBI has not been extensively studied. In the present study, the association between them was investigated. 235 patients with NVAF, 116 cases of SBI without NVAF and 120 cases of healthy volunteers (control group), who did not receive any antithrombotic therapy, were enrolled in this study. Plasma LPA levels in the NVAF with SBI group were significantly higher than that in the control group (p < 0.01), NVAF without SBI group (p < 0.01) and SBI without NVAF group (p < 0.01). The LPA levels are lower in the control group than in the NVAF without SBI and SBI without NVAF groups (p < 0.01), however, the latter two groups did not significantly differ from each other for LPA levels (p > 0.05) There were significant differences in the positive rate of platelet activation between each of the groups (p < 0.01). The positive rate of platelet activation was significantly higher in the NVAF with SBI group. We suggest that LPA might be a novel marker for estimation of the status of platelet activation and the risk factor for SBI onset in NVAF patients. We expected that plasma LPA levels could predict the occurrence of SBI in NVAF patients.
format Text
id pubmed-2996775
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-29967752010-12-08 Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation Li, Zhen-Guang Yu, Zhan-Cai Yu, Yong-Peng Ju, Wei-Ping Wang, Dao-Zhen Zhan, Xia Wu, Xi-Juan Zhou, Li Int J Mol Sci Article Lysophosphatidic acid (LPA), which is proposed to play an important role in normal physiological situations such as wound healing, vascular tone, vascular integrity and reproduction, may be involved in the etiology of some diseases such as atherosclerosis, cancer, obesity or myocardial infarction. Abnormal findings, including silent brain infarction (SBI), are frequently observed by magnetic resonance imaging (MRI) in patients with nonvalvular atrial fibrillation (NVAF). However, whether there is a relationship between LPA level and the prevalence of SBI has not been extensively studied. In the present study, the association between them was investigated. 235 patients with NVAF, 116 cases of SBI without NVAF and 120 cases of healthy volunteers (control group), who did not receive any antithrombotic therapy, were enrolled in this study. Plasma LPA levels in the NVAF with SBI group were significantly higher than that in the control group (p < 0.01), NVAF without SBI group (p < 0.01) and SBI without NVAF group (p < 0.01). The LPA levels are lower in the control group than in the NVAF without SBI and SBI without NVAF groups (p < 0.01), however, the latter two groups did not significantly differ from each other for LPA levels (p > 0.05) There were significant differences in the positive rate of platelet activation between each of the groups (p < 0.01). The positive rate of platelet activation was significantly higher in the NVAF with SBI group. We suggest that LPA might be a novel marker for estimation of the status of platelet activation and the risk factor for SBI onset in NVAF patients. We expected that plasma LPA levels could predict the occurrence of SBI in NVAF patients. Molecular Diversity Preservation International (MDPI) 2010-10-19 /pmc/articles/PMC2996775/ /pubmed/21152315 http://dx.doi.org/10.3390/ijms11103988 Text en © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Li, Zhen-Guang
Yu, Zhan-Cai
Yu, Yong-Peng
Ju, Wei-Ping
Wang, Dao-Zhen
Zhan, Xia
Wu, Xi-Juan
Zhou, Li
Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation
title Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation
title_full Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation
title_fullStr Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation
title_full_unstemmed Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation
title_short Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation
title_sort lysophosphatidic acid level and the incidence of silent brain infarction in patients with nonvalvular atrial fibrillation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996775/
https://www.ncbi.nlm.nih.gov/pubmed/21152315
http://dx.doi.org/10.3390/ijms11103988
work_keys_str_mv AT lizhenguang lysophosphatidicacidlevelandtheincidenceofsilentbraininfarctioninpatientswithnonvalvularatrialfibrillation
AT yuzhancai lysophosphatidicacidlevelandtheincidenceofsilentbraininfarctioninpatientswithnonvalvularatrialfibrillation
AT yuyongpeng lysophosphatidicacidlevelandtheincidenceofsilentbraininfarctioninpatientswithnonvalvularatrialfibrillation
AT juweiping lysophosphatidicacidlevelandtheincidenceofsilentbraininfarctioninpatientswithnonvalvularatrialfibrillation
AT wangdaozhen lysophosphatidicacidlevelandtheincidenceofsilentbraininfarctioninpatientswithnonvalvularatrialfibrillation
AT zhanxia lysophosphatidicacidlevelandtheincidenceofsilentbraininfarctioninpatientswithnonvalvularatrialfibrillation
AT wuxijuan lysophosphatidicacidlevelandtheincidenceofsilentbraininfarctioninpatientswithnonvalvularatrialfibrillation
AT zhouli lysophosphatidicacidlevelandtheincidenceofsilentbraininfarctioninpatientswithnonvalvularatrialfibrillation